Review of anti-obesity medication clinical studies in Arab countries shows growing GLP-1 drug evidence with region-specific efficacy and cultural/access considerations.
Key findingReview of anti-obesity medication clinical studies in Arab countries shows growing GLP-1 drug eviden
What the researchers found
Review of anti-obesity medication clinical studies in Arab countries shows growing GLP-1 drug evidence with region-specific efficacy and cultural/access considerations.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Five databases searched for studies on anti-obesity medications in Arab populations. Most studies were small and observational.
How the study worked
Methodology in publication.
Who was studied
Adult Arab populations across multiple countries
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Clinical studies on anti-obesity medications in Arab countries.
Saudi medical journal, 46(5), 459-477
Citation
AlOtaibi, Haifa F; Al Taib, Hanan N; AlMuhaidib, Shadan; Alshagrawi, Saud; Almufarrih, Abdulmalik; Alalmai, Ola; Alnaserallah, Sahar; Alodah, Najla; Alqahtani, Saleh A; Alhazzani, Waleed. (2025). Clinical studies on anti-obesity medications in Arab countries.. Saudi medical journal, 46(5), 459-477. https://doi.org/10.15537/smj.2025.46.5.20250126